Summary The Complete Clinical Guide to Abnormal Uterine Bleeding & Menstrual Disorders in Reproductive-Age Women

DOCUMENT DESCRIPTION: Overview This is a comprehensive, three-module academic medical study packet meticulously designed for medical students, nursing students, nurse practitioner students, physician assistant students, and clinicians preparing for high-stakes standardized clinical examinations. The central clinical topic is the evaluation, classification, diagnosis, and management of Abnormal Uterine Bleeding (AUB) and Menstrual Disorders in Reproductive-Age Women — consistently ranked among the top five most tested gynecology presentations on USMLE Step 2 CK, ANCC Family and Adult Health NP certification, AANP certification, PANCE/PANRE, and iHuman standardized patient encounter platforms. The complete packet spans over 70 pages across three separate, professionally formatted PDF modules, each serving a distinct and progressive educational purpose: foundational knowledge and pharmacology in Module 1, applied clinical reasoning through full patient encounter simulations in Module 2, and board examination preparation through 25 vignette-style MCQs with expert rationales in Module 3. Every section is grounded in the most current evidence-based guidelines including ACOG Practice Bulletins, FIGO AUB Classification System (2011, updated 2018), ASRM Guidelines, WHO Endometrial Hyperplasia Classification (2014), and Endocrine Society Clinical Practice Guidelines. This document is particularly valuable because AUB is one of the most clinically complex gynecology topics — it simultaneously demands knowledge of endocrinology, oncology, hematology, reproductive medicine, surgical gynecology, and pharmacology. Students who master this topic gain a decisive advantage across multiple examination domains. MODULE 1 — Clinical Revision Masterclass (24 Pages) Module 1 is the comprehensive academic reference and foundational knowledge base of the entire packet. It is structured to mirror the progression of a real clinical encounter — from understanding disease mechanisms, through patient history and physical examination, to diagnostic workup and treatment selection. Section 1 — AUB Terminology & Normal Menstrual Parameters The module opens by establishing the precise clinical language of menstrual disorders, presenting a complete Normal Menstrual Parameters Table covering cycle frequency, cycle regularity, duration of flow, volume of flow, intermenstrual bleeding, postcoital bleeding, and postmenopausal bleeding. Each parameter is paired with its abnormal classification, clinical significance, and the diagnostic implications of deviation from normal. Critical distinctions are established from the outset: polymenorrhea versus oligomenorrhea, heavy menstrual bleeding (HMB) defined as 80 mL per cycle, and the absolute urgency of postmenopausal bleeding as an oncologic red flag. Section 2 — The PALM-COEIN Classification System (FIGO 2011, Updated 2018) The intellectual backbone of the entire document. A comprehensive nine-row classification matrix covers every recognized category of AUB with six-dimensional analysis per condition: full name, structural versus non-structural designation, key pathophysiology, typical clinical presentation, and primary diagnostic tool. The nine categories addressed in full are: P — Polyp (AUB-P): Focal endometrial overgrowth via BCL-2 overexpression and aberrant local estrogen receptor upregulation; presents with intermenstrual and postcoital bleeding; diagnosed by hysteroscopy as the gold standard. A — Adenomyosis (AUB-A): Endometrial glands within the myometrium causing inflammatory hypertrophy; hallmark presentation of heavy bleeding plus severe progressive dysmenorrhea; diagnosed by MRI junctional zone criteria. L — Leiomyoma (AUB-L): Estrogen-dependent benign smooth muscle tumors with symptom severity dictated by anatomical subtype (submucosal most symptomatic); diagnosed by TVUS and MRI fibroid mapping. M — Malignancy and Hyperplasia (AUB-M): The highest-urgency category; endometrial cancer presents in 90% of cases as postmenopausal bleeding; requires mandatory endometrial biopsy. C — Coagulopathy (AUB-C): Von Willebrand Disease as the most common inherited cause; impaired platelet plug formation at spiral arteriole tips; screened with vWF antigen, ristocetin cofactor activity, and Factor VIII. O — Ovulatory Dysfunction (AUB-O): PCOS as the dominant clinical pathway; anovulation producing continuous unopposed estrogen stimulation of the endometrium; irregular, unpredictable breakthrough bleeding. E — Endometrial (AUB-E): Primary endometrial hemostatic defects including excess prostaglandin E2/I2 and impaired fibrinolysis inhibition; diagnosis of exclusion; responds to NSAIDs and tranexamic acid. I — Iatrogenic (AUB-I): Medication-induced bleeding from hormonal contraceptives, anticoagulants, copper IUD, and antipsychotic-induced hyperprolactinemia. N — Not Yet Classified (AUB-N): Chronic endometritis (plasma cell infiltration), arteriovenous malformations, and rare uterine structural anomalies. Section 3 — Seven Pathophysiological Deep Dives Following the classification matrix, seven mechanistic essays provide the level of molecular and cellular understanding required for top-tier examination performance: Normal Menstrual Hemostasis — the five-component hemostatic system (platelet plug, thromboxane A2, tissue factor cascade, PAI-1 fibrinolysis inhibition, endothelin-1 vasomotor tone) and how its disruption generates AUB. PCOS and Anovulatory AUB — the triple pathophysiological pathway of insulin resistance, dysregulated GnRH pulsatility, and follicular arrest producing chronic unopposed endometrial estrogen exposure and irregular breakthrough bleeding; long-term endometrial cancer risk from untreated anovulation. Uterine Fibroids — the FIGO fibroid subclassification (Types 0–8); why submucosal location produces dramatically greater bleeding than intramural or subserosal; racial disparities in prevalence. Endometrial Polyps — BCL-2 anti-apoptotic overexpression; local aromatase activity; malignant transformation risk in postmenopausal women and tamoxifen users; impact on implantation and IVF outcomes. Adenomyosis — direct invasion versus de novo differentiation theories; intramyometrial pressure mechanism generating the globular boggy uterus; MRI junctional zone diagnostic criteria. Von Willebrand Disease — the most missed cause of HMB in adolescents; dual roles of vWF in platelet adhesion and Factor VIII protection; ISTH Bleeding Assessment Tool application; Type 1 versus 2 versus 3 treatment differences. Endometrial Hyperplasia and Cancer — WHO 2014 two-tier classification (with and without atypia); POEM mnemonic for cancer risk factors; 25–33% concurrent cancer risk in atypical hyperplasia; Lynch syndrome implications. Section 4 — The 40% History-Taking Blueprint (Page 4) A complete, systematic history-taking framework organized into five sections mirroring the PALM-COEIN structure, with professionally worded clinical interview questions throughout: Section A — Bleeding Pattern Characterization: Cycle frequency, duration, volume, intermenstrual and postcoital bleeding, dysmenorrhea quality and progression, premenstrual symptom presence (as ovulation marker). Section B — Systemic Impact Assessment: Anemia symptoms, pica (pagophagia as iron deficiency marker), quality of life impact, flooding and leakage. Section C — Structural Cause Screening (PALM): Fibroid-directed questions (bulk symptoms, urinary frequency, constipation), adenomyosis-directed questions (progressive dysmenorrhea, NSAID failure), malignancy risk screening (BMI, PCOS, tamoxifen, Lynch syndrome, PMB). Section D — Non-Structural Cause Screening (COEIN): Coagulopathy bleeding history (menarche onset, epistaxis, bruising, procedure bleeding, family history), ovulatory dysfunction (cycle predictability, thyroid/PCOS/prolactinoma history, hyperandrogenic features, weight/exercise changes), iatrogenic (complete medication review including OTC, supplements, IUD type and placement date). Section E — Complete Gynecologic and Obstetric History: LMP, menarche age, gravida/para, Pap smear history, sexual history, contraceptive method, and — most critically — explicit fertility goal documentation (the single most commonly missed history point in AUB encounters). Section 5 — Physical Examination Protocol (Page 5) A detailed, step-by-step examination guide covering: General appearance: BMI, pallor of conjunctivae and palmar creases, vital signs, thyroid palpation, PCOS stigmata (Ferriman-Gallwey hirsutism scoring, acanthosis nigricans, acne, androgenic alopecia), coagulopathy stigmata (petechiae, ecchymoses). Abdominal examination: Inspection for fibroid-related mass above pubic symphysis, percussion for bladder dullness, palpation for palpable uterine fundus. Speculum examination: Cervical inspection (ectropion, polyp, lesion), active bleeding source localization (uterine vs. cervical vs. vaginal), vaginal wall rugation assessment, specimen collection. Bimanual examination: Four-step protocol — uterine size in weeks equivalent, uterine contour (smooth vs. nodular vs. globular-boggy), uterine mobility (adhesions vs. endometriosis), adnexal assessment (PCOS ovaries, endometrioma, posterior cul-de-sac nodularity). A comprehensive Physical Examination Findings Interpretation Table with eight rows covering globular boggy uterus (adenomyosis), irregular firm uterus (fibroids), fixed retroflexed uterus with cul-de-sac nodularity (endometriosis), cervical polyp, petechiae and ecchymoses (coagulopathy), PCOS triad, pallor and tachycardia (iron deficiency anemia), and urethral caruncle (PMB mimic). Section 6 — Three-Tier Diagnostic Workup Guide (Page 6) A structured, tiered diagnostic framework: Tier 1 — Universal Testing (ALL AUB patients): Urine hCG (mandatory first test), CBC and hemoglobin, iron studies (ferritin as earliest marker), TSH (most commonly missed systemic cause), prolactin, cervical cancer screening. Tier 2 — Targeted Testing (clinical suspicion-directed): PCOS workup (Rotterdam-concordant panel), anovulation confirmation (Day 21 progesterone), coagulopathy panel (vWF antigen + activity + Factor VIII), endometrial biopsy thresholds, chronic endometritis evaluation, prolactinoma MRI criteria. Tier 3 — Imaging and Endoscopy: TVUS (first-line structural imaging), sonohysterography (gold standard for intracavitary lesions), MRI (adenomyosis and fibroid mapping), office hysteroscopy (gold standard for polyps and submucosal fibroids), diagnostic laparoscopy (gold standard for endometriosis). Section 7 — Advanced Pharmacotherapy for Ten Clinical Scenarios (Pages 7–12) The most comprehensive section of Module 1 — a complete pharmacotherapy reference covering ten clinical management scenarios across five-column tables with treatment line, drug and regimen, dose and duration, mechanism of action, and contraindications and key notes: Acute Heavy Menstrual Bleeding Emergency Management — IV conjugated estrogen, high-dose OCP, tranexamic acid IV, desmopressin Levonorgestrel IUD — the most effective non-surgical HMB treatment with Level A ACOG evidence Combined Oral Contraceptives — cyclic and continuous regimens with full contraindication profile Oral Progestins — cyclic endometrial protection and high-dose hyperplasia treatment NSAIDs — non-hormonal first-line for ovulatory HMB with prostaglandin inhibition mechanism GnRH Agonists and Antagonists — leuprolide, elagolix, relugolix with mandatory add-back therapy protocols Tranexamic Acid — antifibrinolytic mechanism, 5-day menstrual-only dosing, VTE contraindication Endometriosis Medical Management — three-tier approach from OCP/progestins through GnRH agents to surgical options Uterine Fibroid Management — comprehensive spectrum from medical temporization through hysteroscopic myomectomy, UAE, abdominal myomectomy, endometrial ablation, and hysterectomy with precise fertility-based indications Endometrial Hyperplasia Management — LNG-IUD versus oral progestin comparison for non-atypical disease; mandatory oncology referral and hysterectomy recommendation for atypical hyperplasia/EIN Section 8 — Ten High-Yield Clinical Pitfalls (Pages 13–16) Each pitfall is structured as a realistic examination scenario, a mechanistic explanation of why the error occurs, and a correct approach framework. The ten pitfalls address: Failing to rule out pregnancy before AUB workup — the ectopic emergency trap Dismissing postmenopausal bleeding as atrophic vaginitis without biopsy — the missed cancer scenario Diagnosing PCOS without meeting Rotterdam criteria — the single-criterion diagnostic error Prescribing ablation or hysterectomy to a woman who desires future pregnancy — the irreversible harm error Not screening for coagulopathy in an adolescent with HMB since menarche — the missed vWD scenario Using GnRH agonist beyond six months without add-back therapy — the preventable bone loss error Misinterpreting irregular cycles as anovulatory without progesterone confirmation — the mistreatment of an ovulatory woman Recommending LNG-IUD with a large cavity-distorting submucosal fibroid — the device failure scenario Failing to identify the endometrial biopsy threshold in premenopausal high-risk AUB — the delayed cancer diagnosis Treating atypical hyperplasia independently without oncology referral — the concurrent cancer risk error The module closes with a comprehensive AUB Management Decision Framework Summary Table and two overarching clinical principle callout boxes synthesizing the entire module's teaching. Who This Document Is For This study packet is specifically designed for: Medical students preparing for USMLE Step 2 CK shelf examinations and clerkship OSCE assessments Nursing and NP students using iHuman simulation platforms and preparing for ANCC or AANP board certification PA students preparing for PANCE and PANRE gynecology content Residents rotating through obstetrics and gynecology, internal medicine, or family medicine Clinicians in primary care, women's health, or urgent care seeking a current, evidence-based rapid reference Students who have previously struggled with AUB classification, distinguishing adenomyosis from fibroids, understanding PCOS diagnostic criteria, or navigating the complex pharmacotherapy landscape of menstrual disorders